Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Aug 20 · above the Ichimoku cloud · RSI 52 · MACD below its signal
| 0.2000 | 52-week high | +203.03% |
| 0.0670 | R3 (classic) | +1.52% |
| 0.0670 | R2 (classic) | +1.52% |
| 0.0670 | R1 (classic) | +1.52% |
| 0.0670 | Pivot | +1.52% |
| 0.0670 | S1 (classic) | +1.52% |
| 0.0670 | S2 (classic) | +1.52% |
| 0.0670 | S3 (classic) | +1.52% |
| 0.0670 | Previous day high | +1.52% |
| 0.0670 | Previous day low | +1.52% |
| 0.0670 | Previous week high | +1.52% |
| 0.0670 | Previous week low | +1.52% |
| 0.0670 | Previous month high | +1.52% |
| 0.0660 | Price now | |
| 0.0360 | Previous month low | −45.45% |
| 0.0320 | 52-week low | −51.52% |
None of the 29 investors followed here reported a position in VYCO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VYCO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VYCO.
TimeframesUp on the hourly and daily, down on the weekly and monthly.
over a rising 21 EMA, 21 over 50
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.1 | 0.0 | -18.2 | -23.3 | 0.0 | -4.3 | 4.5 | -2.9 | 0.0 | -1.5 | −45.5% | ||
| 2025 | -1.4 | 0.0 | -5.8 | 86.2 | -2.5 | 11.9 | -1.5 | -0.8 | 35.7 | -14.3 | 16.7 | -30.9 | +72.9% |
| 2024 | 10.4 | -5.9 | 16.3 | -9.7 | 7.1 | 0.0 | -2.2 | -33.0 | 32.2 | 0.0 | 25.6 | -28.6 | −9.1% |
| 2023 | 3.3 | -2.2 | 2.2 | 0.0 | 0.0 | 3.2 | 0.0 | -1.0 | 0.0 | -13.7 | -20.7 | 18.5 | −14.4% |
| 2022 | -28.6 | 0.0 | 71.4 | 91.7 | -52.2 | 25.5 | -9.4 | -20.8 | -9.1 | 7.8 | 2.1 | -9.1 | −8.2% |
| 2021 | -20.0 | 187.5 | -13.9 | -14.1 | -12.9 | 1.4 | -8.7 | 8.0 | 1.4 | -46.0 | 33.3 | -9.3 | −2.0% |
| 2020 | 15.9 | -21.9 | -64.0 | -24.4 | 191.2 | 40.4 | 94.2 | -25.2 | -1.0 | -1.0 | -30.3 | -27.5 | −27.5% |
| 2019 | 109.8 | 10.5 | -1.1 | 0.0 | -5.9 | -9.6 | 0.0 | -12.5 | -2.1 | 16.8 | -8.1 | -6.1 | +68.3% |
| 2018 | -21.6 | 22.5 | -2.0 | -40.0 | 29.5 | -22.3 | 0.0 | -3.4 | -4.6 | -8.2 | -24.9 | -55.4 | −83.9% |
| 2017 | -26.5 | -13.6 | -7.4 | 4.0 | -5.3 | 52.3 | 0.0 | 0.0 | -6.7 | 21.4 | 14.4 | 31.1 | +50.0% |
| 2016 | -21.4 | -11.8 | -6.7 | -1.8 | -3.8 | 11.3 | -55.2 | 9.8 | 20.7 | 20.0 | 7.1 | -24.4 | −60.7% |
| 2015 | -10.6 | 0.0 | 15.0 | -15.2 | -14.7 | -0.8 | -4.5 | 27.0 | -12.5 | -9.3 | -18.1 | -16.8 | −51.7% |
| 2014 | 12.2 | 0.0 | -18.3 | 3.7 | 26.7 | 9.3 | -2.6 | -1.1 | -15.0 | 4.1 | -9.1 | -14.4 | −12.7% |
| 2013 | 0.0 | 40.0 | 40.5 | -30.5 | 30.7 | -25.7 | -9.5 | 25.0 | 11.1 | -8.4 | -10.5 | +36.7% |
No analyst coverage for this instrument.
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company operates through two segments: Vycor Medical and NovaVision. Its Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement with a German-based partner. It primarily serves hospitals and medical professionals. The company was incorporated in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. operates as a subsidiary of Fountainhead Capital Management Ltd.